Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effekten av intraoperativ bruk av 20 % albumin kombinert med Ringer-laktat versus Ringer-laktat under cytoreduktiv kirurgi med hypertermisk intraperitoneal kjemoterapi: Protokoll for en randomisert åpen klinisk studie (ALBUCHIP)

24. september 2026 oppdatert av: Assistance Publique - Hôpitaux de Paris

Evaluering de l'efficacité du Remplissage Vasculaire Par de l'ALBUmine Humaine 20% + Ringer Lactate sammenlignet med Ringer Lactate Seul Chez Les Patients opérés Par cytoréduction Avec CHimiothérapie Intrapéritonéale hyPerthermique

Introduction Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is considered as the standard of care for the treatment of peritoneal metastases. Cytoreductive surgery with HIPEC is characterized by large intra operative fluid shift secondary to surgical resection, peritoneal inflammation and capillary shifts, requesting high volume of intra operative fluid therapy. Previous studies found a strong association between intra operative hypovolemia or volume overload with post operative outcomes. Albumin as an intravenous fluid has been widely studied in critical ill patients, but evaluation of its efficacy during major surgery on post operative clinical outcomes are lacking. We hypothesize that a reduction of intra operative crystalloid volume infusion by using 20% albumin during CRS with HIPEC could improve patients' prognosis. The aim of this study will be to assess the efficacy of 20% albumin combined with Ringer Lactate versus Ringer Lactate for fluid therapy during CRS with HIPEC on post operative outcome at 28 day.

Methods and analysis The study protocol has been designed and written in accordance with the Prospective randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.

Recruitment, randomisation and allocation Information on the study and screening of patients will be conducted during the consultation of anaesthesia (= selection visit), 2 months at 3 days before the surgery. Information notice and consent form will be delivered. The day before the surgery, anaesthesiologist who will conduct the pre anaesthetic visit will be able to include patients in the study (=inclusion visit). Randomisation will be done at the inclusion visit after information and signature of consent form of voluntary patients. A randomization number will be assigned. The 1:1 randomisation will be centralized via an online interface ensuring secret group assignment, and based on predefined randomisation lists with variable-size permutation blocks, stratified by center. Randomisation will be accomplished using a computer-generated random sequence.

Randomized Open, Blinded endpoint (PROBE) design. This study is a randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.

Intervention

  • 20% Albumin + Ringer Lactate group (intervention group) Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
  • Control group Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.

Outcome measures The primary outcome will be the Comprehensive Complication Index (CCI score) at day 28 after CRS with HIPEC. Secondary outcomes are mortality at day 28, CCI score at day 7, volume of intra operative and post operative (48h) post operative fluid therapy, cumulated incidence of surgical post operative complications, cumulated incidence of medical post operative complications, need for mechanical ventilation, renal replacement therapy between surgery and day 28, SOFA score variation between pre operative period and 48h after surgery, number of days alive out of intensive care unit and out of hospital until day 28

Sample size calculation To ensure a power of 80%, a number of patients 130 (65 patients by group) will be necessary with a reduction of 13.6 (SD 24) points of the CCI score at day 28 in the intervention group. Because of a risk of neoplastic evolution between anaesthetic consultation and randomisation (10% of early cancellation), a total of 146 patients (73 by group) will be included in the study.

Discussion In summary, ALBUCHIP study will be the first randomized clinical trial assessing efficacy of intraoperative use of 20% albumin combined with Ringer Lactate versus Ringer Lactate during CRS with HIPEC. Results yielded from this study will be helpful for vascular filling during CRS with HIPEC but, thanks to ancillary studies, to improve pathophysiological understanding of this surgery.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

140

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Lyon, Frankrike
        • Rekruttering
        • Hôpital Lyon Sud Pierre Bénite
        • Ta kontakt med:
      • Montpellier, Frankrike
        • Rekruttering
        • Institut régional du Cancer de Montpellier
        • Ta kontakt med:
      • Paris, Frankrike, 75013
        • Rekruttering
        • La Pitié Salpetriere hospital
        • Ta kontakt med:
      • Paris, Frankrike
        • Rekruttering
        • Lariboisière hospital
        • Ta kontakt med:
      • Paris, Frankrike
        • Rekruttering
        • Saint Louis hospital
        • Ta kontakt med:
      • Reims, Frankrike
        • Rekruttering
        • Robert Debré hospital
        • Ta kontakt med:
      • Strasbourg, Frankrike
      • Villejuif, Frankrike

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Male and female patients aged 18 years old and older
  • Planned cytoreductive surgery with HIPEC for peritoneal carcinomatosis (from gynaecological or digestive origin)
  • Patient volunteer for the study and provided written informed consent
  • Patient affiliated to the French Health Insurance

Exclusion Criteria:

  • Adults >75 years old
  • Functional status rendering the patient ineligible for cytoreduction with CHIP (ECOG > 2 or Karnofsky index < 75)
  • Pre-existing preoperative conditions affecting albuminemia (hepatic cirrhosis, nephrotic syndrome, exudative enteropathy, malnutrition)
  • Severe preoperative hypoalbuminemia (albuminemia < 20 g/L)
  • History of chronic left heart failure with reduced left ventricular ejection fraction (left ventricular ejection fraction < 40%)
  • Patients at high risk of perioperative and postoperative pulmonary complications (atelectasis, significant pleural effusions)
  • Significant ascites with preoperative respiratory repercussions
  • Uncontrolled diabetes (HbA1c > 8.5%)
  • Allergy to exogenous human albumin and its excipients.
  • Contraindication to the administration of Ringer's lactate (history of allergy)
  • Hyperkalemia > 6.0 mmol/L
  • Hypercalcemia (total calcium > 2.60 mmol/L)
  • Chronic use of digitalis and hyperkalemic diuretics
  • Pregnancy, breastfeeding
  • Known preoperative renal failure (GFR < 30 mL/min/1.73m2 or extrarenal purification)
  • Recent brain trauma < 6 months (traumatic, ischemic, or hemorrhagic)
  • Participation in another interventional study involving human subjects or being in the exclusion period following a previous study involving human subjects, if applicable
  • Patient deprived of liberty
  • Patient under guardianship or curatorship

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: 20% Albumin + Ringer Lactate group

Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.

Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.

Aktiv komparator: Control group

Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.

Ringer lactate

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Comprehensive Complication Index score
Tidsramme: At day 28

The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery.

The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death

At day 28

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Volum av intraoperativ og postoperativ væskebehandling
Tidsramme: 48 timer etter operasjonen
48 timer etter operasjonen
Kumulativ forekomst av kirurgiske postoperative komplikasjoner
Tidsramme: Frem til dag 28
Frem til dag 28
Antall dager i live utenfor intensivavdelingen
Tidsramme: Frem til dag 28
Frem til dag 28
Antall dager i live ute av sykehus
Tidsramme: Frem til dag 28
Frem til dag 28
Forekomst av infeksjonskomplikasjoner
Tidsramme: Frem til dag 28
Frem til dag 28
Forekomst av medisinske komplikasjoner
Tidsramme: Opp til dag 28
Opp til dag 28
Kumulativ forekomst av dødsfall på intensivavdeling
Tidsramme: Opp til dag 28
Opp til dag 28
Kumulativ forekomst av død på sykehus
Tidsramme: Opp til dag 28
Opp til dag 28
Antall dager med vasopressorer
Tidsramme: Opp til dag 28
Opp til dag 28
Andel pasienter med allergiske komplikasjoner til albumin
Tidsramme: På dag 133
På dag 133
Comprehensive Complication Index score
Tidsramme: At day 7

The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery.

The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death

At day 7
Number of days under mechanical ventilation outside the operating room
Tidsramme: Up to day 28

Between surgery and day 28

Up to day 28
Number of days under renal replacement therapy
Tidsramme: Up to day 28

Between surgery and day 28

Up to day 28
Sequential organ failure assessment (SOFA) score variation
Tidsramme: 48 hours after surgery

Between pre operative period and 48h after surgery

48 hours after surgery
SOFA score
Tidsramme: At day 28

Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function

At day 28

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

3. september 2025

Primær fullføring (Antatt)

1. oktober 2027

Studiet fullført (Antatt)

1. oktober 2027

Datoer for studieregistrering

Først innsendt

2. april 2024

Først innsendt som oppfylte QC-kriteriene

2. april 2024

Først lagt ut (Faktiske)

8. april 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. september 2026

Sist bekreftet

1. november 2025

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere